109 related articles for article (PubMed ID: 6296575)
1. New enkephalinase inhibitors as probes to differentiate "enkephalinase" and angiotensin-converting-enzyme active sites.
Roques BP; Fournié-Zaluski MC; Florentin D; Waksman G; Sassi A; Chaillet P; Collado H; Costentin J
Life Sci; 1982 Oct 18-25; 31(16-17):1749-52. PubMed ID: 6296575
[No Abstract] [Full Text] [Related]
2. [Enkephalinase inhibitors and molecular study of the differences between active sites of enkephalinase and angiotensin-converting enzyme].
Roques BP
J Pharmacol; 1985; 16 Suppl 1():5-31. PubMed ID: 2993752
[TBL] [Abstract][Full Text] [Related]
3. In vivo 'enkephalinase' inhibition by acetorphan in human plasma and CSF.
Spillantini MG; Geppetti P; Fanciullacci M; Michelacci S; Lecomte JM; Sicuteri F
Eur J Pharmacol; 1986 Jun; 125(1):147-50. PubMed ID: 3015640
[TBL] [Abstract][Full Text] [Related]
4. Degradation of neurotensin by rat brain synaptic membranes: involvement of a thermolysin-like metalloendopeptidase (enkephalinase), angiotensin-converting enzyme, and other unidentified peptidases.
Checler F; Vincent JP; Kitabgi P
J Neurochem; 1983 Aug; 41(2):375-84. PubMed ID: 6308159
[TBL] [Abstract][Full Text] [Related]
5. Degradation of exogenous enkephalin in the guinea-pig ileum: relative importance of aminopeptidase, enkephalinase and angiotensin converting enzyme activity.
Geary LE; Wiley KS; Scott WL; Cohen ML
J Pharmacol Exp Ther; 1982 Apr; 221(1):104-11. PubMed ID: 6278132
[No Abstract] [Full Text] [Related]
6. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.
Gros C; Noël N; Souque A; Schwartz JC; Danvy D; Plaquevent JC; Duhamel L; Duhamel P; Lecomte JM; Bralet J
Proc Natl Acad Sci U S A; 1991 May; 88(10):4210-4. PubMed ID: 1851998
[TBL] [Abstract][Full Text] [Related]
7. Rat brain enkephalinase: characterization of the active site using mercaptopropanoyl amino acid inhibitors, and comparison with angiotensin-converting enzyme.
Gordon EM; Cushman DW; Tung R; Cheung HS; Wang FL; Delaney NG
Life Sci; 1983; 33 Suppl 1():113-6. PubMed ID: 6319849
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological "enkephalinase" inhibition in man.
Marcello F; Grazia SM; Sergio M; Federigo S
Adv Exp Med Biol; 1986; 198 Pt B():153-60. PubMed ID: 3028074
[TBL] [Abstract][Full Text] [Related]
9. Enantiomers of [R,S]-thiorphan: dissociation of analgesia from enkephalinase A inhibition.
Scott WL; Mendelsohn LG; Cohen ML; Evans DA; Frederickson RC
Life Sci; 1985 Apr; 36(13):1307-13. PubMed ID: 2984500
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterization of enkephalinase, angiotensin converting enzyme, and a third peptidyldipeptidase from rat brain.
Cushman DW; Gordon EM; Wang FL; Cheung HS; Tung R; Delaney NG
Life Sci; 1983; 33 Suppl 1():25-8. PubMed ID: 6319870
[TBL] [Abstract][Full Text] [Related]
11. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.
Roques BP; Fournié-Zaluski MC; Soroca E; Lecomte JM; Malfroy B; Llorens C; Schwartz JC
Nature; 1980 Nov; 288(5788):286-8. PubMed ID: 7001254
[TBL] [Abstract][Full Text] [Related]
12. Novel selective thiol inhibitors of neutral endopeptidase containing heterocycles at P'2 position.
Norcini G; Morazzoni G; Pocchiari F; Santangelo F; Semeraro C
J Enzyme Inhib; 1997 Jun; 12(2):155-60. PubMed ID: 9247857
[No Abstract] [Full Text] [Related]
13. Enkephalin metabolism in brain and its inhibition.
Schwartz JC; De La Baume S; Yi CC; Chaillet P; Marcais-Collado H; Costentin J
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):665-71. PubMed ID: 6298893
[TBL] [Abstract][Full Text] [Related]
14. Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan.
Roques BP; Lucas-Soroca E; Chaillet P; Costentin J; Fournié-Zaluski MC
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3178-82. PubMed ID: 6304695
[TBL] [Abstract][Full Text] [Related]
15. Enkephalinase is involved in the degradation of endogenous substance P released from slices of rat substantia nigra.
Mauborgne A; Bourgoin S; Benoliel JJ; Hirsch M; Berthier JL; Hamon M; Cesselin F
J Pharmacol Exp Ther; 1987 Nov; 243(2):674-80. PubMed ID: 2445957
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor.
Lecomte JM; Costentin J; Vlaiculescu A; Chaillet P; Marcais-Collado H; Llorens-Cortes C; Leboyer M; Schwartz JC
J Pharmacol Exp Ther; 1986 Jun; 237(3):937-44. PubMed ID: 3519939
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dipeptidyl carboxypeptidase and endopeptidase activities in the three enkephalin-hydrolysing metallopeptidases: "angiotensin-converting enzyme", thermolysin and "enkephalinase".
Malfroy B; Schwartz JC
Biochem Biophys Res Commun; 1985 Jul; 130(1):372-8. PubMed ID: 2992465
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme, enkephalinase A and aminopeptidases in the breakdown of enkephalin--studies in cell cultures.
Lentzen H; Reinsch I; Linke J
Clin Exp Hypertens A; 1984; 6(10-11):1829-32. PubMed ID: 6099767
[TBL] [Abstract][Full Text] [Related]
19. The metabolism of neuropeptides. Neurokinin A (substance K) is a substrate for endopeptidase-24.11 but not for peptidyl dipeptidase A (angiotensin-converting enzyme).
Hooper NM; Kenny AJ; Turner AJ
Biochem J; 1985 Oct; 231(2):357-61. PubMed ID: 2998348
[TBL] [Abstract][Full Text] [Related]
20. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors.
Fournie-Zaluski MC; Lucas E; Waksman G; Roques BP
Eur J Biochem; 1984 Mar; 139(2):267-74. PubMed ID: 6321177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
